Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLTogether1 for newly diagnosed acute lymphoblastic leukemia
2018-001795-38Phase 3Active
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of blinatumomab, doxorubicin, dexamethasone, vincristine, methotrexate and 7 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Event-free survival. Started Nov 2019; status: active.
02
Drugs
blinatumomabdoxorubicindexamethasonevincristinemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2018-001795-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001795-38.